Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02101853 · OUTCOME

Rates of Minimal Residual Disease (MRD) Positivity (> 0.01%)

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia · Source last updated 2026-07-29

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 12 weeks

What was measured

The rates at the end of Block 2 and Block 3 will be calculated for the randomized arms for HR and IR relapse patients.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
The rates at the end of Block 2 and Block 3 will be calculated for the randomized arms for HR and IR relapse patients.
reporting Status
NOT_POSTED
time Frame
Up to 12 weeks
title
Rates of Minimal Residual Disease (MRD) Positivity (> 0.01%)
type
OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice